Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total

P 2 (1)

P 4 (1)

Trial Status

Completed3

Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT05442632Phase 2RecruitingPrimary

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

NCT03979417CompletedPrimary

Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets

NCT02087371CompletedPrimary

Prognosis Factors of Cardiac Complications After Liver Transplantation

NCT03121521Phase 4CompletedPrimary

The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment

Showing all 4 trials

Hepatopathy